内镜光动力微创疗法治疗胆管癌的临床疗效分析

doi:10.3969/j.issn.1009-976X.2014.03.003

摘要/Abstract

摘要： 【摘要】〓目的〓探讨内镜光动力微创疗法(PDT)联合支架置入术治疗胆管癌的临床疗效。方法〓将2005年10月至2009年6月我院收治的62例胆管癌患者分为两组,对照组32例,给予内镜下支架置入术;治疗组30例,在支架置入术的基础上,给予内镜下光动力治疗。对62例晚期胆管癌患者的生存时间及生活质量进行随访。结果〓经过3年以上的随访,治疗组中位生存时间18个月,1、2、3年生存率分别为63.3%、43.3%及20.0%;对照组中位生存时间8个月,1、2、3年生存率分别为43.8%、25.0%及9.4%,生活质量FACT-Hep量表术后6个月、9个月及12个月,治疗组量表总分明显高于对照组(P<0.05),术前胆红素水平、远处转移及治疗方法是影响胆管癌患者生存期的独立预后因子。结论〓内镜光动力微创疗法(PDT)联合支架置入术提高了胆管癌患者的生存率,改善了生活质量,是胆管癌一种有效的治疗方法。

关键词: 胆管癌, 光动力疗法, 内镜治疗, 生存期

Abstract: 【Abstract】 Objective To evaluate the efficacy of endoscopic photodynamic therapy combined with stent implantation on cholangiocarcinoma..Methods Sixty-two cases of patients with cholangioc-arcinoma from October 2005 to June 2009 in our hospital were divided into two groups,.32 cases in the control group were treated by endoscopic stent placement,.and 30 cases in the treatment group were treated with the endoscopic stent placement combined with photodynamic therapy. The follow-up was done in 62 cases,.including survival time and quality of life..Results After 3years of follow-up, the median overall survival time of treatment group was 18 months,.the 1-,.2- and 3-year survival rate were 63.3%, 43.3%, and 20.0%, respectively. The median overall survival time of control group was 8 months, the 1-, 2- and 3-year survival rate were 43.8%, 25.0% and 9.4%, respectively. The total score of FACT-Hep scales in treatment group were higher than those in control group at postoperative 6 months,.9 months and 12 months(P<0.05). Cox multivariate analysis demonstrated that among the factors analyzed,.the level of bilirubin,.lymph node status,.and therapeutic method were independent prognostic factors for overall survival in patients with cholangiocarcinoma..Conclusion Endoscopic photodynamic therapy combined with stent implantation improves survival and quality of life, and is an effective treatment for patients with cholangiocarcinoma.

Key words: Cholangiocarcinoma, Photodynamic therapy, Endoscopic treatment, Survival time

中图分类号:

李悦张大伟薛平卢海武郑强曹良启. 内镜光动力微创疗法治疗胆管癌的临床疗效分析[J]. 岭南现代临床外科, 2014, 14(03): 235-238.

Li Yue, Zhang Dawei, Xue Ping, Lu Haiwu, Zheng Qiang, Cao Liangqi. Clinical efficacy of endoscopic photodynamic therapy on cholangiocarcinoma[J]. Lingnan Modern Clinics in Surgery, 2014, 14(03): 235-238.

参考文献

Yoon JH, Gores GJ: Diagnosis, Staging, and Treatment of Cholangiocarcinoma. Current treatment options in gastroenterology 2003, 6(2):105-112.
Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC: Changing international trends in mortality rates for liver, biliary and pancreatic tumours. Journal of hepatology 2002, 37(6):806-813.
朱兆承, 郎庆波, 陈喆, 等. 肝胆肿瘤治疗功能评定量表中文版的考评[J].中西医结合学报,2008,6(4)：341-345.
Berr F, Wiedmann M, Tannapfel A, et al. Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. Hepatology, 2000,31(2): 291-298.
Kiesslich T, Berlanda J, Plaetzer K, et al. Comparative characterization of the efficiency and cellular pharmacokinetics of Fosca- and Foslip-based photodynamic treatment in human biliary tract cancer cell lines. Photochem Photobiol Sci, 2007, 6(6):619-627.
Witzigmann H, Berr F, Ringel U, et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg, 2006,244(2):230-239.
Dumoulin FL，Gerhardt T，Fuchs S，et al. Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma．Gastrointest Endosc，2003，57(7)：860一867．
Wiedmann M, Caca K, Berr F, et al. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase II pilot study. Cancer, 2003,97(11):2783-2790.
Kahaleh M, Mishra R, Shami VM, et al. Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone versus stenting with photodynamic therapy. Clin Gastroenterol Hepatol, 2008,6(3):290-297.
Shim CS, Cheon YK, Cha SW, et al. Prospective study of the effectiveness of percutaneous transhepatic photodynamic therapy for advanced bile duct cancer and the role of intra-ductal ultrasonography in response assessment. Endoscopy, 2005,37(5):425-433.
Zoepf T, Jakobs R, Arnold J. C, et al. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol, 2005,100(11): 2426-2430.
Heffernan N, Cella D, Webster K, et al. Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire[J]. J Clin Oncol, 2002, 20(9): 2229-2239.

[1]	王忠辉, 陈国林, 苏树英. 安罗替尼联合信迪利单抗治疗复发性胆管癌1例[J]. 岭南现代临床外科, 2022, 22(06): 582-587.
[2]	刘钊远, 蒋小峰, 薛平. 胆管癌的光动力治疗[J]. 岭南现代临床外科, 2021, 21(05): 495-499.
[3]	林志文, 刘红枝, 曾永毅. 肝内胆管癌淋巴结清扫的热点与争议[J]. 岭南现代临床外科, 2021, 21(04): 377-382.
[4]	彭宁福, 钟鉴宏, 朱少亮, 廖迎阳, 黎乐群. 胆管癌、胰腺癌及其癌前病变共同特征的研究现状[J]. 岭南现代临床外科, 2020, 20(02): 261-266.
[5]	林杰，王卫东*，刘清波，马靖. 肝吸虫性胆管炎误诊为胆管癌病例分析[J]. 岭南现代临床外科, 2018, 18(05): 533-536.
[6]	吴海丰袁阳春林嘉瑜谢阗罗育青. 术前PTBD对肝门部胆管癌的疗效及安全性分析[J]. 岭南现代临床外科, 2017, 17(03): 275-277.
[7]	范仁根. 半肝联合肝动脉切除治疗三种类型肝门胆管癌临床分析[J]. 岭南现代临床外科, 2015, 15(03): 273-276.
[8]	费凛. 内镜治疗腹腔镜胆道术后胆漏[J]. 岭南现代临床外科, 2015, 15(03): 276-279.
[9]	洪清琦何传超徐鋆耀胡斌王捷. 肝细胞癌中HBx的表达及其与患者预后的关系[J]. 岭南现代临床外科, 2014, 14(01): 26-29.
[10]	惠栓侯东生. 光动力疗法治疗恶性肿瘤作用机制的研究进展[J]. 岭南现代临床外科, 2013, 13(02): 161-164.
[11]	黄奋陈汝福周泉波李海刚. NF-кB、MUC1在肝内胆管结石合并肝内胆管癌组织的表达和意义 [J]. 岭南现代临床外科, 2010, 10(01): 1-4.